|20/08/01||TGEM055||Enucleated mesenchymal stem cell (MSC) loaded with various functional molecules and biologics||TGEM055 is a disruptive new platform of therapeutics based on MSC-utilized technologies (de-nucleated, payload-carrying, designer-cell capabilities).
- Nuclear DNA Removal
- Fully Functioning Cell-Like Entity with 3-5 day Life Span
- Robust Chemosensing, Migration, and Disease Homing Potential
- Functional Protein Synthesis Machineries “Cell Factories
- Manufactural scalable, "off the shelf"-allogeneic and biobankable
|20/07/30||TGEM054||A fusion protein from two unique monoclonal antibody scfv sequences||TGEM054 is a novel monoclonal antibody technology which works against several cancers.
The architecture of the fusion protein is the key that locks onto a bio-marker expressed in cancer cells. Our antibody fusion protein causes apoptosis 75 % in 7 days with two doses in vitro. It has produced molecules of high caliber tested on 24 cancer cell lines with great results. (100% of cervical cancer, 90% of bladder cancer, 90% of liver cancer ).
|20/07/20||TGEM053||Intranasal drug delivery||This novel Nose-to-Brain formulation allows the delivery of different molecule types (small molecules, peptides, etc.) to the brain, bypassing the blood-brain barrier and travelling along the olfactory and trigeminal nerves. This is more efficient than intravenous injection, elicits a faster onset of pharmacological activity, and requires a lower dose while ensuring a high brain concentration and low systemic concentration. This reduces side effects which are caused by the drug’s systemic action. The simple administration can be in the form of drops, sprays, pumps, cotton swabs, etc. This novel nanoparticle formulation is biodegradable and therefore safe, and can also be administered via sub-lingual, transdermal and possibly oral routes. The patent was submitted in 2020.||問合せ|
|20/06/18||TGEM052||DNA plasmid for Immunotherapies||Our original vector is designed to take manufacturing from outside the patient to inside the patient, using the patient's own cells to manufacture the necessary protein-, DNA- and RNA-based treatments.||問合せ|
|20/05/27||TGEM051||Technologies for recreating extracellular matrix-driven cancer progression and quantifying the effects of therapeutics||Hyaluronic acid in the tumour microenvironment presents biochemical cues that drive cancer progression. Biomimetic hydrogels with hyaluronic acid are used recreate mechanisms of cancer progression to visualise the spread of cancer from local invasion to metastasis in an organ-on-a-chip. Machine vision constructs 3D maps for each patient sample in the organ-on-a-chip to track the location and health of cancer cells. Treatments are tested in parallel to compare their effects on halting cancer progression. Applications include target/drug discovery and patient selection for translational and clinical trials.||問合せ|
|20/05/08||TGEM050||AI for Small molecule discovery service||TGEM050 performs multi-property inverse QSAR/QSPR, powered by generative AI, to discover novel, efficacious, safe, and synthesizable drug like compounds. Properties to be optimized are defined by the customer: pharmacological activity, synthesizability, ADME, and toxicity. TGEM050 can output any number of molecular structures defined by the customer, and can be re-run quickly to generate more optimized structures based on feedback.||問合せ|
|20/05/07||TGEM049||AI based predictions for best candidate drugs||AI/ML drug discovery platform technology that predicts protein-small molecule activity. The platform can predict activity for not well characterized protein targets that have only primary sequence data available.
This technology enables ultra high-speed screening for activity and specificity. The platform can be used in a wide array of applications to discover novel and repurposable drugs. It can be used for scanning molecule libraries for COVID-19 at the shorter term.
|20/04/08||TGEM048||Manufacturing and use of stem cell-derived active substances||Supernatant containing stem cell-derived multiple substances which enable promoting gene expression related to tissue engineering such as growth factors. The supernetant may be used for cosmetics, and pharmaceuticals for the treatment of atopic dermatosis, alzheimer and reumatoid arthritis.||問合せ|
|20/03/06||TGEM047||Innovative transparent film-forming and bioadhesive delivery technology||TGEM047 is a versatile topical bioadhesive film-forming vehicle (platform) with occlusive or semi occlusive characteristics and sustained release properties for an adequate vehiculization of lipophilic and hydrophilic components. It can also be used as a vehicle for the inclusion of other technologies (micro, liposome, nanoparticles etc). This technology has been successfully applied to different topical molecules demonstrating an improvement on the API's bioavailability profile as well as providing more adequate formulations for patient treatment adherence.||問合せ|
|20/03/06||TGEM046||Proliferation control of Mononegavirales using photoswitching system||Mononegavirales are promising tools as oncolytic vectors and transgene delivery vectors for gene therapy and regenerative medicine. By using the specifically designed proteins, which reversibly heterodimerize upon blue light illumination, photocontrollable mononegaviruses (measles and rabies viruses) were generated. The proteins were inserted into the flexible domain of the viral polymerase, and the oncolytic virus showed strong replication and oncolytic activities only when the viral polymerases were activated by blue light illumination. Treatment of this oncolytic virus resulted in a substantial reduction in tumor growth and prolonged survival under the blue light.||問合せ|